<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001296</url>
  </required_header>
  <id_info>
    <org_study_id>920105</org_study_id>
    <secondary_id>92-C-0105</secondary_id>
    <nct_id>NCT00001296</nct_id>
  </id_info>
  <brief_title>A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma</brief_title>
  <official_title>A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Randomized study. Initially, 3 patients will be entered on Arm I as a pilot feasibility study&#xD;
      and to standardize the technical aspects of the study. Subsequently, all patients are&#xD;
      randomized to Arms I and II.&#xD;
&#xD;
      Arm I: Regional Hyperthermia plus Regional Single-Agent Chemotherapy. Hyperthermic&#xD;
      intravenous limb perfusion, HILP; plus Melphalan, L-PAM, NSC-8806.&#xD;
&#xD;
      Arm II: Regional Hyperthermia plus Regional Single-Agent Chemotherapy and Biological Response&#xD;
      Modifier Therapy. HILP as in Arm I; plus L-PAM; and Tumor Necrosis Factor (Knoll), TNF,&#xD;
      NSC-635257; Interferon gamma (Genentech), IFN-G, NSC-600662.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with locally advanced melanoma confined to an extremity (Stage IIIA or Stage IIIAB)&#xD;
      will be treated in a randomized Phase III study with hyperthermic isolated limb perfusion.&#xD;
      One arm of the study will be a standard 60 minute perfusion with melphalan as a single agent.&#xD;
      The second arm of the study will combine melphalan, tumor necrosis factor, and&#xD;
      interferon-gamma in the isolated limb perfusion reproducing a regimen shown to have 100%&#xD;
      response rates in a Phase II European trial. Patients will be followed for local response&#xD;
      rates, duration of response, treatment toxicity, and disease-free survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1992</start_date>
  <completion_date>October 2000</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>122</enrollment>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tumor necrosis factor</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon-gamma</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyperthermic isolated limb perfusion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Biopsy-proven Stage IIIA or IIIAB melanoma (M.D. Anderson staging system) of an extremity,&#xD;
        as follows:&#xD;
&#xD;
        Advanced local disease indicated by 2 or more satellite or in-transit metastases.&#xD;
&#xD;
        Lower limb regional metastases must be distal to the apex of the femoral triangle except&#xD;
        inguinal lymph node metastases.&#xD;
&#xD;
        Upper limb regional metastases must be distal to the deltoid insertion except axillary&#xD;
        lymph node metastases.&#xD;
&#xD;
        No evidence of systemic disease outside the involved extremity.&#xD;
&#xD;
        Recurrent disease subsequent to prior successful limb perfusion allowed.&#xD;
&#xD;
        Bidimensional directly measurable dermal or subcutaneous lesion required.&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
        No prior isolated limb perfusion.&#xD;
&#xD;
        Biologic Therapy: At least 1 month since Biologic Therapy.&#xD;
&#xD;
        At least 3 months since regional therapy of the extremity.&#xD;
&#xD;
        Chemotherapy: At least 1 month since chemotherap.y&#xD;
&#xD;
        At least 3 months since regional therapy of the extremity.&#xD;
&#xD;
        Endocrine Therapy: Not specified.&#xD;
&#xD;
        Radiotherapy: At least 1 month since radiotherapy.&#xD;
&#xD;
        Surgery: Not specified.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 18 and over.&#xD;
&#xD;
        Performance status: ECOG 0 or 1.&#xD;
&#xD;
        Hematopoietic: Platelets greater than 150,000.&#xD;
&#xD;
        Hepatic: Bilirubin less than 1.5 mg/dl; Coagulation profile normal.&#xD;
&#xD;
        Renal: Creatinine less than 2.0 mg/dl.&#xD;
&#xD;
        Cardiovascular: No evidence of peripheral vascular disease, e.g.:&#xD;
&#xD;
        No history of claudication.&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
        HIV negative.&#xD;
&#xD;
        No pregnant or nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Karakousis CP, Choe KJ, Holyoke ED. Biologic behavior and treatment of intransit metastasis of melanoma. Surg Gynecol Obstet. 1980 Jan;150(1):29-32.</citation>
    <PMID>7350699</PMID>
  </reference>
  <verification_date>November 1999</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Interferon-Gamma</keyword>
  <keyword>Isolated Limb Perfusion</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Melphalan</keyword>
  <keyword>TNF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

